Mekonos: Coupling digital microfluidics with nanoengineered MEMS onto a single integrated chip for cell/gene therapies
Gene and cell therapy will never be the same with Mekonos’ groundbreaking delivery technology. Using frontier research in microfluidics and MEMS engineering, they have built a single chip system that can deliver variable size, cell precision, payloads achieving unmatched cell delivery yield and viability. This could forever change the development of therapies, and with previously unachievable scalability could mean genetic based cures to those who need them faster than ever hoped.
"Mekonos and TDK Ventures share synergistic values in our commitment to contribute and enrich society in building a better world. They are also known leaders in the MEMS industry with valuable experience in manufacturing. We look forward to this monumental opportunity to collaborate moving forward, and to work together to bring about new hope and therapies for families everywhere struggling with illness and limited treatment options."